Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks myelin — the protective sheath surrounding nerve fibers. The result is progressive neurological dysfunction, affecting mobility, cognition, and quality of life. Conventional treatments slow progression, but do not repair existing damage. Mesenchymal stem cell (MSC) therapy is being studied as a way to do both.
Why MSCs Are Relevant to MS
MSCs have two properties directly relevant to MS: immunomodulation and neuroprotection. In MS, an overactive immune response drives demyelination. MSCs suppress the inflammatory T-cell and B-cell activity responsible for this damage by shifting the immune balance from a pro-inflammatory state (Th1, Th17 cells) to an anti-inflammatory state (regulatory T-cells, Tregs). They reduce the release of IFN-γ, IL-17, and TNF-α — key drivers of MS pathology — while increasing IL-10 production.
Additionally, MSCs secrete neurotrophic factors — BDNF and GDNF — that protect neurons from degeneration and may promote remyelination by supporting oligodendrocyte progenitor cells (OPCs), the cells that generate new myelin.
What Published Research Shows
Immunomodulatory Effect
A study published in Lancet Neurology reported that patients with progressive MS who received MSC therapy demonstrated reduced inflammation markers in cerebrospinal fluid and decreased activity of pro-inflammatory immune cells — associated with a reduction in the frequency and severity of relapses.
Neuroprotection Confirmed in Pre-Clinical Models
A study published in Nature Neuroscience demonstrated that MSCs protected neurons from damage by promoting the survival of neurons and oligodendrocytes (cells that form myelin in the CNS). Treated animals had reduced nerve damage and improved neurological outcomes.
Remyelination Potential
One of the most significant findings is that MSCs can differentiate into oligodendrocyte progenitor cells — the cells responsible for regenerating the myelin sheath. This provides a mechanism not just for slowing further demyelination but for actual myelin repair, which is beyond the reach of conventional disease-modifying therapies.
The Regen Cord Protocol for MS
At True Regen Medical, MS protocols are coordinated with our lab partner Regen Cord, which manufactures Wharton's jelly MSCs under ISO/cGMP standards. Administration method — intrathecal (directly into the spinal canal) versus intravenous, or a combination — depends on the MS subtype and disease stage, and is determined by your physician on your evaluation call.
Treatment is typically delivered over 3–5 days. Patients generally return to their home country within one week. Monthly telemedicine follow-up begins at 30 days post-treatment.
Who Is a Candidate?
Not every MS patient is a suitable candidate. Factors our physicians evaluate include: disease subtype (relapsing-remitting vs. secondary progressive vs. primary progressive), current EDSS score, prior treatment history, and any contraindications. The evaluation call is where we determine this honestly — we decline patients where the risk/benefit profile does not clearly favor treatment.
If you have MS and are exploring your options, submit your records for a free physician review. We will tell you directly whether we believe MSC therapy is appropriate for your case.